Research discussion is not a recommendation. Do not buy or use unauthorized products, including products labelled “research use only” or “not for human consumption.”

What it is

CJC-1295 is an investigational analogue designed to influence growth-hormone-releasing hormone signalling. Online products may use the name for different formulations, including versions described as containing a drug-affinity complex.

What the evidence can tell us

Early human studies examined pharmacology and hormone responses in small groups. Those findings do not establish broad anti-aging, muscle-building, fat-loss, recovery, or wellness benefits, and they do not validate products sold by unrelated vendors.

Canadian context

Health Canada’s 2026 advisory names CJC-1295 among unauthorized injectable peptide drugs. No authorized CJC-1295 drug product was identified in the Drug Product Database on the date checked.

Key unknowns

Long-term clinical benefit and safety are not established. Products sold outside an authorized supply chain also present uncertainty about identity, concentration, formulation, sterility, and contaminants.

Source trail

Primary sources

  1. Health Canada - 2026 injectable peptide advisory
  2. Health Canada - Drug Product Database
  3. PubMed - CJC-1295 clinical pharmacology study
Status can change. Check Health Canada’s Drug Product Database and the exact finished product before relying on this profile. This page is general education, not medical advice or a product recommendation. Full disclaimer.